Literature DB >> 8698485

Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection.

T M Daly1, C A Long.   

Abstract

Previously, we described a protective immune response induced by the carboxyl-terminal region of the merozoite surface protein-1 (MSP-1) from the rodent malarial parasite Plasmodium yoelii yoelii 17XL, expressed as a fusion protein and designated glutathione S-transferase (GST)-PYC2. We also demonstrated that the humoral response induced by GST-PYC2 was the primary mechanism by which immunized animals controlled their blood-stage infections. We have now examined the influence of several adjuvants on the immune response to the GST-PYC2 fusion protein. While alum, Freund's adjuvant, Ribi adjuvant system, and TiterMax were efficacious in eliciting a protective response with GST-PYC2 in BALB/c mice, saponin failed to induce protection, although significant levels of PYC2-specific antibodies were produced in all immunized animals. This protection depended on the mouse strain since immunization of Swiss Webster mice with GST-PYC2 in alum did not produce levels of PYC2-specific antibodies comparable to those in BALB/c mice nor did it induce any demonstrable level of protection against parasite challenge. Swiss Webster mice were protected, however, when immunized with GST-PYC2 in other adjuvants. Immunization with PYC2, isolated free of GST induced lower levels of antigen-specific antibody; only those animals given PYC2 in Freund's adjuvant demonstrated a significant degree of protection, suggesting the possibility (of additional cellular effector mechanisms. These findings demonstrate that adjuvant, host genotype, and the fine specificity of the response significantly influence the protection induced by the carboxyl terminus of MSP-1 in vivo and illustrate the need to consider these factors in evaluating MSP-1 as a vaccine component.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698485      PMCID: PMC174116          DOI: 10.1128/iai.64.7.2602-2608.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Immunological cross-reactivity of the C-terminal 42-kilodalton fragment of Plasmodium falciparum merozoite surface protein 1 expressed in baculovirus.

Authors:  G S Hui; C Hashiro; C Nikaido; S E Case; A Hashimoto; H Gibson; P J Barr; S P Chang
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

Review 2.  Immunity to blood stages of malaria.

Authors:  C A Long
Journal:  Curr Opin Immunol       Date:  1993-08       Impact factor: 7.486

3.  Sequence conservation in the C-terminal part of the precursor to the major merozoite surface proteins (MSP1) of Plasmodium falciparum from field isolates.

Authors:  S Jongwutiwes; K Tanabe; H Kanbara
Journal:  Mol Biochem Parasitol       Date:  1993-05       Impact factor: 1.759

4.  A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice.

Authors:  T M Daly; C A Long
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

Review 5.  Copolymer adjuvants in malaria vaccine development.

Authors:  R L Hunter; A A Lal
Journal:  Am J Trop Med Hyg       Date:  1994       Impact factor: 2.345

6.  Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines.

Authors:  T L ten Hagen; A J Sulzer; M R Kidd; A A Lal; R L Hunter
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

7.  Sequence heterogeneity of the C-terminal, Cys-rich region of the merozoite surface protein-1 (MSP-1) in field samples of Plasmodium falciparum.

Authors:  Y Kang; C A Long
Journal:  Mol Biochem Parasitol       Date:  1995-07       Impact factor: 1.759

8.  Regulation of antibody specificity to Plasmodium falciparum merozoite surface protein-1 by adjuvant and MHC haplotype.

Authors:  S P Chang; C M Nikaido; A C Hashimoto; C Q Hashiro; B T Yokota; G S Hui
Journal:  J Immunol       Date:  1994-04-01       Impact factor: 5.422

9.  Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1.

Authors:  J A Chappel; A A Holder
Journal:  Mol Biochem Parasitol       Date:  1993-08       Impact factor: 1.759

10.  Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein.

Authors:  M J Blackman; T J Scott-Finnigan; S Shai; A A Holder
Journal:  J Exp Med       Date:  1994-07-01       Impact factor: 14.307

View more
  22 in total

1.  Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.

Authors:  George S Hui; Caryn N Hashimoto
Journal:  Int Immunopharmacol       Date:  2008-04-03       Impact factor: 4.932

2.  Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.

Authors:  C Yang; W E Collins; J S Sullivan; D C Kaslow; L Xiao; A A Lal
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

3.  Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites.

Authors:  Qifang Shi; Amy Cernetich; Thomas M Daly; Gina Galvan; Akhil B Vaidya; Lawrence W Bergman; James M Burns
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Protective immunity against Plasmodium yoelii malaria induced by immunization with particulate blood-stage antigens.

Authors:  J M Burns; P D Dunn; D M Russo
Journal:  Infect Immun       Date:  1997-08       Impact factor: 3.441

5.  Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.

Authors:  James R Alaro; Michele M Lynch; James M Burns
Journal:  Vaccine       Date:  2010-08-13       Impact factor: 3.641

6.  Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.

Authors:  Suraksha Sachdeva; Gul Ahmad; Pawan Malhotra; Paushali Mukherjee; V S Chauhan
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

7.  Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.

Authors:  James M Burns; Patrick R Flaherty; Payal Nanavati; William P Weidanz
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Roles of the Maltese cross form in the development of parasitemia and protection against Babesia microti infection in mice.

Authors:  Naoaki Yokoyama; Sabine Bork; Mitsuhiro Nishisaka; Haruyuki Hirata; Tomohide Matsuo; Noboru Inoue; Xuenan Xuan; Hiroshi Suzuki; Chihiro Sugimoto; Ikuo Igarashi
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

9.  Pathways for potentiation of immunogenicity during adjuvant-assisted immunizations with Plasmodium falciparum major merozoite surface protein 1.

Authors:  G S Hui; C N Hashimoto
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

10.  A chimeric Plasmodium falciparum merozoite surface protein vaccine induces high titers of parasite growth inhibitory antibodies.

Authors:  James R Alaro; Andrea Partridge; Kazutoyo Miura; Ababacar Diouf; Ana M Lopez; Evelina Angov; Carole A Long; James M Burns
Journal:  Infect Immun       Date:  2013-07-29       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.